Esomeprazole: Update and clinical review

Reviews in Gastroenterological Disorders

Volumn 2, Issue 4, 2002, Pages 189-199

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Erosive esophagitis; Esomeprazole; Gastroesophageal reflux disease; Omeprazole magnesiumn

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ANTIBIOTIC AGENT; ATTAPULGITE; DIGOXIN; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; NON PRESCRIPTION DRUG; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; WARFARIN;

ABDOMINAL PAIN; ADULT; CLINICAL STUDY; CLINICAL TRIAL; CONSUMER; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG LABELING; DRUG SAFETY; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HUMAN; MALE; REFLUX ESOPHAGITIS; REVIEW; TABLET; UNITED STATES;

ANTI-ULCER AGENTS; CLINICAL TRIALS; DRUG LABELING; ENZYME INHIBITORS; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; OMEPRAZOLE; PROTON PUMPS;

EID: 0036764299     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Prilosec [package insert]. Wilmington, Del: Astra-Zeneca LP; 2001.
2. OTC Omeprazole Magnesium (Prilosec 1™) Review Team. Memorandum regarding NDA 21-229: Prilosec 1 (omeprazole magnesium) for OTC use. Center for Drug Evaluation and Research. Food and Drug Administration. May 23, 2002. Available at: http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3861B1Summary%20memo.pdf. Accessed August 13, 2002
3. Shetty D. OTC medical officer's review: Prilosec 1 (omeprazole magnesium) - NDA 21-229. Center for Drug Evaluation and Research. Food and Drug Administration. April 26, 2002. Available at: http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3861B1Actual%20use.pdf. Accessed August 13, 2002
4. Nexium [package insert]. Wilmington, Del: Astra-Zeneca LP; 2001.
5. Sachs G, Shin JM. Pharmacological basis for different rates of recovery of acid secretion after PPI treatment Presented at: Digestive Disease Week; May 19-22, 2002; San Francisco, CA. Abstract 103241.
6. Baisley K, Warrington S, Tejura B. et al. Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers (abstract]. Gut. 2002;50:299.
7. Röhss K. Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci. 2002;47:954-958.
8. Baisley K, Warrington S, Tejura B, et al. Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers. Presented at: Digestive Disease Week; May 19-22, 2002; San Francisco, CA. Abstract 101759.
9. Andersson T, Rohss K, Hassan-Alin M, Bredberg E. Pharmacokinetics (PK) and dose response relationship of esomeprazole (E) (abstract]. Gastroenterology. 2000;118(4 Suppl 2):5550.
10. Andersson T, Bredberg E, Sunzel M, et al. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (0) and its 2 optical isomers, S-omeprazole/esomepmzole (E) and R-omeprazole (R-0) [abstract). Gastroenterology. 2000;118(4 Suppl 2):5551.
11. Procter & Gamble Company & AstraZeneca LP. Advisory committee briefing document for omeprazole magnesium tablets - NDA #21-229. May 6, 2002. Available at: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3861b1octorGamble-Zeneca. pdf. Accessed August 13, 2002
12. OTC Omeprazole Magnesium (Prilosec 1™) Review Team. Prilosec 1 (omeprazole magnesium) - NDA 21-229. Center for Drug Evaluation and Research. Food and Drug Administration. September 19, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3861B1_07_Summary.pdf. Accessed August 13, 2002
13. Avigan M. Medical officer's review: omeprazole magnesium (Prilosec 1™) for OTC use - NDA 21-229. Center for Drug Evaluation and Research. food and Drug Administration. January 27, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3861B1_09_Safety.pdf. Accessed August 13, 2002
14. Baker, DE. Esomeprazole magnesium (Nexium). Rev Gastroenterol Disord. 2001;1:32-41.
15. Chatur N, Halparin I, Whittaker JS, et al. Esomeprazole 40 mg once a day, is more cost effective and does not result in worse symptom control in patients using proton pump inhibitors (PPIs) twice a day: preliminary results. Presented at: Digestive Disease Week; May 19-22, 2002; San Francisco, CA. Abstract 108181.
16. Vakil NB, Shaker R, Johnson DA, et. al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001;15:927-935.
17. Talley NJ, Lauritsen Y, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther. 2001;15:347-354.
18. Lauritsen K, Junghard O, Eklund S, Wiklund I. The effect of esomeprazole 40 mg on healing, reflux symptoms and quality of life in patients with reflux esophagitis. Presented at: Digestive Disease Week; May 19-22, 2002; San Francisco, Calif. Abstract 102308.
19. Lauritsen K, Junghard O, Eklund S. Esomeprazole 20 mg compared with lansoprazole 15 mg for maintenance therapy in patients with healed reflux esophagitis. J Gastroenteral Hepatol. 2002;17(Suppl.) A1007 Abstract: L.B.034
20. Lauritsen K, Junghard O, Eklund S. Esomeprazole 20 mg compared with lansoprazole 15 mg for maintenance therapy in patients with healed erosive esophagitis (EE). Presented at: Digestive Disease Week; May 19-22, 2002; San Francisco, Calif. Abstract 102795.
21. Lauritsen K, Junghard O, Eklund S. Esomeprazole 20 mg compared with lansoprazole 15 mg for maintenance therapy in patients with healed reflux oesophagitis [abstract]., Gut. 2002;50:450.
22. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole In GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroexterol. 2001;96:656-665.
23. Howden CW, Ballard ED, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Invest. 2002;22:99-109.
24. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575-583.
25. Johnson DA, Vakil NB, Richter J, et al. Sustained heartburn resolution during the first 4 weeks of PPI therapy predicts subsequent healing in GERD patients with erosive esophagitis. Presented at: Digestive Disease Week; May 19-22, 2000: San Francisco, Calif. Abstract 102934.
26. Castell DO, Richter J, Vakil NB, et al. Sustained heartburn resolution is a good predictor of subsequent symptom status in GERD patients with erosive, esophagitis. Presented at: Digestive Disease Week; May 19-22, 2002: San Francisco Calif. Abstract 103148.
27. Eissele R, Gatz G, Hole U. Pantoprazole 40 mg and esomeprazole 40 mg show equivalent healing rates in patient with GERD. Presented at: Digestive Disease Week; May 19-22, 2002; San Francisco, Calif. Abstract 102778.